Jalra

RSS

vildagliptin

Authorised
This medicine is authorised for use in the European Union.

Overview

Jalra is a diabetes medicine that is used together with diet and exercise to control the blood glucose (sugar) in adults with type 2 diabetes. It is used alone when metformin (another diabetes medicine) is not suitable, or together with other diabetes medicines, including insulin, when these medicines do not provide adequate control of the blood glucose. 

Jalra contains the active substance vildagliptin.

This EPAR was last updated on 09/09/2021

Authorisation details

Product details
Name
Jalra
Agency product number
EMEA/H/C/001048
Active substance
vildagliptin
International non-proprietary name (INN) or common name
vildagliptin
Therapeutic area (MeSH)
Diabetes Mellitus, Type 2
Anatomical therapeutic chemical (ATC) code
A10BH02
Publication details
Marketing-authorisation holder
Novartis Europharm Limited
Revision
22
Date of issue of marketing authorisation valid throughout the European Union
19/11/2008
Contact address

Vista Building
Elm Park
Merrion Road
Dublin 4
Ireland

Product information

21/07/2021 Jalra - EMEA/H/C/001048 - IG1421/G

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Dipeptidyl peptidase 4 (DPP-4) inhibitors
  • Drugs used in diabetes

Therapeutic indication

Vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:

  • as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance.
  • in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating